PL BioScience GmbH
Edit

PL BioScience GmbH

https://www.pl-bioscience.com/
Last activity: 13.08.2024
Active
Categories: BioTechCultureDevelopmentGrowthHealthTechHumanProductProductionResearchTechnology
We at PL BioScience are experts in cell culture supplements derived from human Platelets. Our mission is to enhance the advances in cellular research and therapy with one forward-looking Technology: ELAREM™.

The ELAREM™ Platform unites tailored cell culture supplements based on Human Platelet Lysate. The human origin combined with a rich growth factor content not only supports cell growth, but also enables various applications: The products cover all needs of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from lab to patients in need.

Our story goes back to 2015 and the idea to deliver animal component-free cell culture supplements. Today, we have changed the possibilities of cell expansion: Researchers switch from Fetal Bovine Serum to our animal suffering-free products. Stem Cell Therapy benefits the regeneration potential of our platelet-derived products. And we keep moving forward.

Let's create the future of cell expansion together and join us on our mission.
Followers
208
Mentions
4
Location: Germany, North Rhine-Westphalia, Aachen
Employees: 11-50
Founded date: 2015

Investors 2

Mentions in press and media 4

DateTitleDescription
13.08.2024The Green Gold Rush: Demecan's Rise in the European Cannabis MarketThe cannabis industry is blooming in Europe, and Demecan is at the forefront of this green revolution. With a recent funding boost, the company is inching closer to a staggering 100 million euros in valuation. This is not just a number; it ...
12.08.2024Knime erhält 30 Millionen – PL BioScience sammelt 7,8 Millionen ein – Shoepassion kauft MybudapesterIm #DealMonitor für den 12. August werfen wir einen Blick auf die wichtigsten, spannendsten und interessantesten Investments und Exits des Tages in der DACH-Region. Alle Deals der Vortage gibt es im großen und übersichtlichen #DealMonitor-A...
19.05.2021Risikokapital für technologieorientierte Start-ups im westlichen Rheinland: Investoren weiten TechVision Fonds I nochmals aus auf 55 Mio. €Investorenkreis um Sparkasse Neuss und zwei Privatinvestoren vergrößert
-PL BioScience“Animal-free cell culture supplements derived from human platelets. Supporting cell expansion and maintenance from research to therapy.”

Reviews 0

Sign up to leave a review

Sign up Log In